Myriad Genetics, Inc. MYGN
NASDAQ
| 09/30/2026 | 06/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 6.29% | -4.84% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 6.29% | -4.84% | |||
| Cost of Revenue | 2.04% | 1.43% | |||
| Gross Profit | 8.43% | -7.70% | |||
| SG&A Expenses | 7.24% | 3.76% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.66% | 1.73% | |||
| Operating Income | -2.57% | -53.75% | |||
| Income Before Tax | -2.35% | -24.93% | |||
| Income Tax Expenses | -50.00% | -- | |||
| Earnings from Continuing Operations | -1.62% | -26.69% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1.62% | -26.69% | |||
| EBIT | -2.57% | -53.75% | |||
| EBITDA | -3.41% | -106.25% | |||
| EPS Basic | -0.66% | -25.23% | |||
| Normalized Basic EPS | -1.35% | -46.76% | |||
| EPS Diluted | 0.00% | -26.41% | |||
| Normalized Diluted EPS | -1.35% | -46.76% | |||
| Average Basic Shares Outstanding | 0.95% | 1.17% | |||
| Average Diluted Shares Outstanding | 0.95% | 1.17% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||